+------------------------------------------------------------------------------+
Buy Actelion, May Be 20% Upside to 2016 Consensus EPS, UBS Says 2014-06-17 03:51:39.523 GMT
By Roger Neill June 17 (Bloomberg) -- UBS reiterates buy, raises PT to SF120 vs SF100 on positive Selexipag data. * Expects upcoming presentation of full Phase III data to provide additional confidence Selexipag will be a blockbuster: UBS * This additional data, including post-hoc analysis, should be presented at CHEST 2014 on Oct. 25-30: UBS * Sees significant upside on Selexipag peak sales, Opsumit peak sales, Opsumit Gross margin * NOTE on June 16: Actelion Rises Most in 2 Yrs After Positive Selexipag Data * Actelion earnings forecasts For Related News and Information: First Word scrolling panel: FIRST<GO> First Word newswire: NH BFW<GO>
To contact the reporter on this story: Roger Neill in London at +44-20-7673-2867 or rneill3@bloomberg.net Morwenna Coniam